GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Piramal Pharma Ltd

Piramal Pharma: Q2 FY27 Standalone Revenue Rs. 1,345.38 Crores, Net Profit Rs. 170.74 Crores

RESULTS ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 27 Oct 2026, 08:59 PM IST  ·  BSE ID: a430b420-6763-4136-8692-1e13ba2292f3
View Original BSE Filing (PDF)
💡
In Simple Terms
Piramal Pharma's revenue grew to Rs. 1,345.38 Crores in Q2 FY27, with net profit at Rs. 170.74 Crores.
🤖 AI Summary
  • Piramal Pharma reported standalone revenue from operations of Rs. 1,345.38 Crores for Q2 FY27.
  • Net profit after tax for the quarter ended September 30, 2026, was Rs. 170.74 Crores.
  • Basic Earnings Per Share (EPS) for Q2 FY27 stood at Rs. 1.29 (restated, not annualised).
  • Total assets as of September 30, 2026, increased to Rs. 12,176.43 Crores from Rs. 11,753.27 Crores on March 31, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
1,345.38 Rs. in Crores
19.35%
Net Profit after tax (Q2 FY27)
170.74 Rs. in Crores
-13.04%
Basic EPS (Q2 FY27)
1.29 Rs.
-12.84%
Total Assets (September 30, 2026)
12,176.43 Rs. in Crores
🏢 How This Affects the Company
📈
Business Impact
The company's standalone revenue from operations increased to Rs. 1,345.38 Crores in Q2 FY27, compared to Rs. 1,127.26 Crores in the corresponding prior period.
💰
Financial Impact
Net profit after tax was Rs. 170.74 Crores for Q2 FY27. Total assets increased to Rs. 12,176.43 Crores as of September 30, 2026, from Rs. 11,753.27 Crores as of March 31, 2026.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported financial performance, including a basic EPS of Rs. 1.29 for the quarter.
🔍
Management Signal
The financial results indicate management's performance in revenue generation and cost management during the quarter and half-year period.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — check revenue growth and net profit trends.
Review consolidated financial results for a complete performance overview.
Management commentary on factors impacting net profit margins.
MEDIUM RISK Growth in revenue is offset by a decline in net profit and EPS year-over-year.
💡 Investor Takeaway
Piramal Pharma's standalone Q2 FY27 revenue from operations increased to Rs. 1,345.38 Crores, up 19.35% YoY. However, net profit after tax for the quarter was Rs. 170.74 Crores, down 13.04% YoY from Rs. 196.33 Crores in Q2 FY26.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone revenue from operations increased by 19.35% to Rs. 1,345.38 Crores in Q2 FY27 from Rs. 1,127.26 Crores in Q2 FY26.
  • Total assets grew by Rs. 423.16 Crores to Rs. 12,176.43 Crores as of September 30, 2026, from Rs. 11,753.27 Crores on March 31, 2026.

⚠️ Concerns

  • Net Profit after tax decreased by 13.04% to Rs. 170.74 Crores in Q2 FY27 from Rs. 196.33 Crores in Q2 FY26.
  • Basic EPS declined to Rs. 1.29 in Q2 FY27 from Rs. 1.48 in Q2 FY26, a decrease of 12.84%.
📅 Company Track Record
Piramal Pharma reported standalone Q1 FY27 revenue up 16.0% YoY to Rs. 1,124.95 Crores in its previous filing on July 29, 2026. This Q2 FY27 filing continues to update the quarterly performance trend for the company.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is Piramal Pharma's standalone revenue from operations for Q2 FY27?
Piramal Pharma's standalone revenue from operations for the quarter ended September 30, 2026 (Q2 FY27) was Rs. 1,345.38 Crores.
What was Piramal Pharma's net profit after tax in Q2 FY27?
The net profit after tax for Piramal Pharma in Q2 FY27 was Rs. 170.74 Crores, compared to Rs. 196.33 Crores in the corresponding period of the previous year.
What is the Basic Earnings Per Share (EPS) for Piramal Pharma in Q2 FY27?
Piramal Pharma reported a Basic Earnings Per Share (EPS) of Rs. 1.29 for Q2 FY27, down from Rs. 1.48 in Q2 FY26.
What are Piramal Pharma's total assets as of September 30, 2026?
As of September 30, 2026, Piramal Pharma's total assets stood at Rs. 12,176.43 Crores.
How did Piramal Pharma's Q2 FY27 revenue compare to Q1 FY27?
Piramal Pharma's Q2 FY27 revenue from operations of Rs. 1,345.38 Crores increased from Q1 FY27 revenue of Rs. 1,124.95 Crores.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.